Obesity-PSA relationship: A new formula

Prostate Cancer and Prostatic Diseases

Volumn 13, Issue 2, 2010, Pages 186-190

  Hekal, I A ^a   Ibrahiem, E I ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

BMI; Equation; Obesity; PSA; Screening test

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OBESITY; PRIORITY JOURNAL; PROSTATE BIOPSY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

ADULT; AGE FACTORS; AGED; ALGORITHMS; BODY MASS INDEX; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; OBESITY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 77952545045     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2009.53     Document Type: Article

References (18)

1. Gray MA, Delahunt B, Fowles JR, Weinstein P, Cookes RR, Nacey JN. Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res 2004;24:2069-2072.
2. Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology 2005;66:819-823.
3. Kristal AR, Chi C, Tangen CM, Goodman PJ, Etzioni R, Thompson IM. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 2006;106:320-328.
4. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008;72:1102-1105.
5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a communitybased population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-864.
6. National Heart Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res 1998;6(Suppl 2):51S-210S.
7. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004;38:732-744.
8. Barqawi AB, Golden BK, O'Donnell C, Brawer MK, Crawford ED. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 2005;65:708-712.
9. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J et al. The association of body mass index and prostatespecific antigen in a population-based study. Cancer 2005;103:1092-1095.
10. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-353.
11. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. Am J Clin Pathol 2003;119:80-89.
12. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-2280. (Pubitemid 350146217)
13. Moul JW. Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Eur Urol 2008;54:232-233.
14. Buschemeyer III WC, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007;52:331-343.
15. Kim YJ, Han BK, Hong SK, Byun SS, Kim WJ, Lee SE. Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol 2007;14:1009-1012.
16. Hekal IA. The patients less than 50 years: is there a need to lower the PSA cutoff point? Prostate Cancer Prostatic Dis 2009;12:148-151.
17. Dahle SE, Chokkalingam AP, Gao Y-T, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;168:599-604.
18. Hammarsten J, Hogstedt B. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 2001;39:151-158.